In vivo mRNA CAR-T for Mast-Cell Driven Allergies
Severe allergic diseases and anaphylaxis
Pre-clinicalActive
Key Facts
Indication
Severe allergic diseases and anaphylaxis
Phase
Pre-clinical
Status
Active
Company
About AllerGene AI Therapeutics
AllerGene AI Therapeutics is a private, preclinical-stage biotech founded in 2020 and based in Boston, MA. The company is developing a novel in vivo CAR-T platform that uses transient mRNA to train the body's T cells to selectively remove mast cells, thereby treating and potentially preventing severe allergic reactions and anaphylaxis. Its approach combines targeted lipid nanoparticle delivery with AI-powered research tools to advance its programs. The company is led by a small team of experienced cell therapy innovators and advisors with deep expertise in immunology and drug development.
View full company profile